Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Monotherapy in Type 2 Diabetes
NCT00094757Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in A1C at 18 weeks. Started Oct 2004; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00094757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094757.